Showing 3371-3380 of 4165 results for "".
- Researchers Use Patients’ Cells to Test Gene Therapy for a Form of Leber Congenital Amauroshttps://modernod.com/news/researchers-use-patients-cells-to-test-gene-therapy-for-a-form-of-leber-congenital-amauros/2478810/Scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy for a rare disease that causes severe vision loss in childhood. A form of Leber congenital amaurosis, the disease is caused by autosomal-dominant mutations in the CRX gene, which are ch
- Market Scope: Refractive Surgery to Grow 9.6% a Year Through 2025, Despite COVID-19https://modernod.com/news/market-scope-refractive-surgery-to-grow-9-6-a-year-through-2025-despite-covid-19/2478774/Expanding use of products to treat refractive error will increase the role of devices and surgical procedures in the refractive landscape, according to a new Market Scope report. Globally, over 2.3 billion people require vision correction and have access to ophthalmic care. Global demand f
- James Reid Named CEO of Versant Healthhttps://modernod.com/news/james-reid-named-ceo-of-versant-health/2478762/MetLife announced that James Reid has been named CEO of Versant Health, a managed vision care company and wholly owned subsidiary of MetLife. The appointment is effective April 1. “James brings extensive and varied experience in the Group Benefits market to Versant Health,” Todd Katz, chai
- Sifi Launches Well Fusion Presbyopia Correcting Systemhttps://modernod.com/news/sifi-launches-well-fusion-presbyopia-correcting-system/2478688/SIFI announces the launch of the Well Fusion system and the Mini Well Proxa IOL, offering a novel solution that provides cataract patients the option to treat presbyopia with spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions. SIFI has develope
- Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseaseshttps://modernod.com/news/gyroscope-therapeutics-and-the-university-of-pennsylvania-announce-research-agreement-to-develop-gene-therapies-for-serious-eye-diseases/2478679/Gyroscope Therapeutics announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope
- Alsanza Announces Global Launch of Alsee Zero Glistening, Zero Haze Hydrophobic Monofocal IOLhttps://modernod.com/news/alsanza-globally-launches-zero-glistening-zero-haze-hydrophobic-monofocal-iol-alsee/2478652/Germany-based Alsanza announced the launch of the Alsee Zero Glistening Zero Haze Hydrophobic Monofocal IOL. The Alsee IOL is developed and designed to provide long-term clarity and high-contrast sensitive quality of vision with its 24-hour aspheric optic design. Alsee Zero Glistening Zero
- Kerry Solomon First in US to Implant Alcon’s Vivity IOLhttps://modernod.com/news/kerry-solomon-first-in-nation-to-implant-alcons-vivity-iol/2478619/Kerry Solomon, MD, partner at Carolina Eyecare Physicians, Charleston, South Carolina, is the first in the United States following FDA approval to complete surgery using Alcon’s AcrySof IQ Vivity Extended Range of Vision IOL, according to a news release. “The Vivity lens is a remarka
- New Survey Finds Critical Need for Education on Cataracts and Modern Treatment Optionshttps://modernod.com/news/new-survey-finds-critical-need-for-education-on-cataracts-and-modern-treatment-options/2478601/Johnson & Johnson Vision announced findings from a new survey that assessed awareness of cataracts among adults around the world. Cataracts are the leading cause of blindness globally,[1] with more than 90% of people developing cataracts by age
- NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreementhttps://modernod.com/news/novabay-pharmaceuticals-expands-avenovas-geographic-reach-to-australia-with-new-exclusive-distribution-agreement/2478586/NovaBay Pharmaceuticals announced the signing of an agreement with Paragon Care Group Australia Pty for the exclusive distribution of Avenova in Australia. Paragon Care Group will begin distributing Avenova directly to consumers under its Designs For Vision brand beginning in early 2021. “
- Alcon Canada Introduces AcrySof IQ Vivity Presbyopia-Correcting IOLhttps://modernod.com/news/alcon-canada-introduces-acrysof-iq-vivity-presbyopia-correcting-iol/2478568/Alcon has announced the Canadian launch of AcrySof IQ Vivity presbyopia-correcting IOL. AcrySof IQ Vivity uses a non-diffractive design called X-WAVE technology and provides an extended range of vision and reduced dependency on glasses following cataract surgery.